Personalised Medicine - Bridgehead International enhances its services

Bridgehead International is pleased to announce an affiliation with Natalie A. Cummins, of DHC Consulting. Through this affiliation, Bridgehead’s services will be expanded to offer payer expertise in the area of personalized medicine, including marketplace assessments, product coverage determinations and reimbursement strategy. In addition, the affiliation strengthens Bridgehead’s existing expertise in the diagnostic market access space, based on Ms. Cummins’ experience at Quest Diagnostics, working with converging technologies, and conducting strategic planning for diagnostic companies.

Natalie is a partner at DHC Consulting, directly responsible for the healthcare and life sciences division, providing consulting services focused on strategic planning, business development, formulating strategic growth plans and optimizing revenue potential. Natalie has nearly 20 years experience working with payers, diagnostic companies and healthcare delivery organizations.  She has extensive diagnostics experience in strategic product evaluation, prioritization and implementation.  

Prior to consulting, Natalie was responsible for international marketing and communications at Synarc, a pharmaceutical services organization, specializing in medical imaging, patient recruitment and biochemical markers.  Natalie’s experience also includes working for Quest Diagnostics, with direct responsibility for health plan and payer marketing.  Natalie earned a Bachelor of Science Degree in Health Administration from Ithaca College and a Masters of Public Administration focused on Health Policy Analysis from New York University.

This era of personalized medicine is complicated and dynamic. The affiliation between Bridgehead and Natalie Cummins will bring diagnostic companies, pharmaceutical companies, and payers a combined personalized medicine perspective focused on capturing the value of innovation from multiple stakeholder perspectives.     

To learn more about Bridgehead’s services in this area, contact Susan Garfield, Vice President, at 508-258-8008 or via email at susan.garfield@bridgehead.com. 

About Bridgehead

Bridgehead International is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.  Our mission is to work with commercial organisations, government agencies and the investment community to ensure that:

  • Life science organisations have the funding, structure and strategic focus to deliver high levels of innovation and financial return
  • Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 40 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience.

Bridgehead is globally recognised for its expertise in:

  • Technical and commercial evaluation
  • Due diligence and Experts’ Reports
  • Forecasting and valuation
  • Market access
  • Pricing and reimbursement strategy
  • Health economics and health technology assessment. 

In 2007, Bridgehead was honoured with The Queen’s Award for Enterprise, in the International Trade section, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards